Climb Bio Inc (NASDAQ: CLYM) is a clinical-stage biopharmaceutical company developing immunology therapeutics with no approved products or commercial revenue as of the 10-K filed March 5, 2026. The company funds operations entirely through equity financing and investment income, not product sales. Its two active pipeline programs are budoprutug and CLYM116, with direct R&D spending of $25.0 million and $12.0 million respectively in FY2025. Total operating expenses were $67.9 million in FY2025, against a net loss of $59.9 million. Interest income of $8.3 million in FY2025 is the only recurring cash inflow, earned on the $160.7 million in cash, cash equivalents, and marketable securities held as of December 31, 2025. The company estimates that cash position funds operations into 2028. Aoife Brennan, M.B., Ch.B. serves as President and CEO. The company is headquartered in Wellesley Hills, Massachusetts.

Revenue model

No product revenue. Operations are funded through equity issuances and the company earns interest income on its cash and marketable securities, totaling $8.3 million in FY2025. All pipeline milestone and royalty payment obligations are contingent on future development and regulatory events.

Products and services

Budoprutug (direct R&D spend of $25.0 million in FY2025) and CLYM116 (direct R&D spend of $12.0 million in FY2025), both in clinical development. Legacy programs incurred $0.1 million in FY2025. CLYM116 was added following an in-process R&D acquisition from a related party recognized in FY2024.

Customers and end markets

No commercial customers as of the filing date. End markets are immunology therapeutics subject to FDA regulatory approval and, if approved, reimbursement by Medicare, Medicaid, and commercial insurers.

Value-chain role

Clinical-stage drug developer. Relies on contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) for nonclinical studies, clinical trials, and manufacturing supply.

Geographic exposure

Headquartered in Wellesley Hills, Massachusetts. Operations are primarily U.S.-based per the filing; foreign currency losses were $0.3 million in FY2025, indicating limited non-U.S. activity.

Source: SEC 10-K, filed 2026-03-05

Industry: Pharmaceutical Preparations Peers: Adverum Biotechnologies, Inc. Bioxytran Inc Checkpoint Therapeutics, Inc. Cypherpunk Technologies Inc Galectin Therapeutics Inc Q32 Bio Inc Immunic Inc Longeveron Inc SPECTRUM PHARMACEUTICALS INC